 |
市場調查報告書
NTRK遺傳基因融合陽性癌症的開發平台醫藥品:市場機會的評估，市場趨勢，流行病學的研究，開發中產品分析 (2020年下半年)NTRK Gene Fusion Positive Cancers Pipeline Drugs - Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2020 |
||||||
| 出版商 | GervanoRA Data Services LLP | 商品編碼 | 979839 | ||||
| 出版日期 | 內容資訊 | 英文 290 Pages  |
|||||
| 價格 |
|
||||||
| NTRK遺傳基因融合陽性癌症的開發平台醫藥品:市場機會的評估，市場趨勢，流行病學的研究，開發中產品分析 (2020年下半年) NTRK Gene Fusion Positive Cancers Pipeline Drugs - Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2020 | ||
| 出版日期: 2020年12月30日 | 內容資訊: 英文 290 Pages |
|
本報告提供全球NTRK融合遺傳基因陽性固體癌治療藥的開發平台醫藥品的市場相關分析，疾病概要和疫情趨勢預測，未滿足需求與市場機會，主要的資本交易的趨勢 (M&A，事業合作等)，開發中產品的分析與臨床實驗的進展，現在、未來的競爭環境，主要企業的SWOT分析，新企業的簡介與市場機會等資訊彙整，為您概述為以下內容。
GervanoRA's pipeline analysis and opportunity assessment report "NTRK Gene Fusion Cancers - Opportunity Assessments, Market Dynamics, Epidemiological Studies, and Pipeline Analytics H2 2020" provides detailed analytics on the Epidemiology of NTRK Gene Fusion Cancers in different regions worldwide through a keen full assessment on historical and global trends of prevalence and incidence of NTRK gene fusion-positive cancers. Based on a literature survey and further validation through the KOL process, the report emphasizes finding out the affected population with NTRK gene fusion-positive cancers by geography (US, Europe, and Worldwide) and by majorly affected cancer types. The report even provides insights on TRK Inhibitors' foreseen market opportunities considering the TRK Inhibitor therapies are the only option to treat NTRK gene fusion-positive cancers. Report further analyzed and assessed the total forecasted market into two portions considering broader scope the TRK Inhibitors to treat indications like Neurodegenerative Diseases, Gastrointestinal Diseases and addiction conditions other than NTRK gene fusion-positive cancers. The report outlines how many people can undergo TRK Inhibitor therapies by 2029, and potential market value of NTRK gene fusion-positive cancers, and the market value of TRK Inhibitors meant to treat other indications other than NTRK gene fusion-positive cancers.
TRK Inhibitors pipeline molecules have been analysed for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in TRK Inhibitor drugs development pipeline.
The report has been divided into segments like TRK InhibitorsTherapies Overview and Epidemiological Studies, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the TRK Inhibitors area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in TRK Inhibitors drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of Development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target, Pipeline Analytics by Indication and Pipeline Analytics by Company Type.
The report has covered more than 50 companies worldwide, involved in the development of new therapeutics. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 10 Emerging companies in the domain and hence deriving the key leader.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:
Epidemiological Studies of NTRK Gene Fusion Positive Cancers
Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.
